Table 4.
Clinical and laboratory features of Turkish patients with type 2 diabetes and control subjectsa
| Parameter | Control Subjects(n = 34) | Patients with Type 2 Diabetes(n = 79) |
|---|---|---|
| Age (yr; mean ± SD) | 41 ± 6 | 42 ± 5 |
| Gender (M/F) | 17/17 | 45/34 |
| BMI (kg/m2; mean ± SD) | 29 ± 3 | 30 ± 2 |
| eGFR (ml/min per 1.73 m2; mean ± SD) | 114 ± 5 | 112 ± 8 |
| Duration of diabetes (mo) | – | 50 (35 to 74) |
| MAP (mmHg; median [range]) | 115 (102 to 120) | 116 (101 to 122) |
| Total cholesterol (mmol/L; mean ± SD) | 4.9 ± 0.2 | 5.0 ± 0.6 |
| Triglycerides (mmol/L; median [range]) | 1.5 (1.3 to 1.8) | 1.5 (0.9 to 2.1) |
| HDL cholesterol (mmol/L; median [range]) | 1.1 (0.9 to 1.3) | 1.0 (0.6 to 1.3) |
| Serum albumin (g/dl; mean ± SD) | 4.1 ± 0.3 | 3.6 ± 0.5b |
| HbA1c (%; mean ± SD) | 4.1 ± 1.8 | 8.5 ± 1.6b |
| Plasma insulin (μ IU/ml; median [range]) | 7.7 (6.0 to 10.7) | 11.9 (8.2 to 29.9)b |
| Plasma glucose (mmol/L; mean ± SD) | 4.8 ± 0.6 | 7.8 ± 1.3b |
| HOMA index (mean ± SD) | 1.6 ± 0.4 | 4.7 ± 1.7b |
| UPE (mg/24 h; mean ± SD; median [range]) | 67 (20 to 140) | 590 (200 to 3450)b |
| hsCRP (mg/L; median [range]) | 2.0 (1.0 to 3.3) | 10.0 (5.0 to 24.0)b |
| PTX3 (ng/ml; median [range]) | 1.4 (0.4 to 2.8) | 7.4 (1.3 to 31.4)b |
| CIMT (mm; mean ± SD) | 0.56 ± 0.05 | 0.60 ± 0.05b |
| FMD (%; mean ± SD) | 9.7 ± 0.9 | 8.2 ± 0.8b |
a
CIMT, carotid intima media thickness; eGFR, estimated GFR; FMD, flow-mediated dilation; HOMA, homeostasis model assessment; UPE, urine protein excretion.
b
Significant difference, P < 0.001.